Illumina Inc. announced on July 30, 2025, the launch of TruSight Oncology 500 version 2 (TSO 500 v2), the next generation of its flagship cancer research assay. This enhanced solution is designed to accelerate access to comprehensive genomic profiling (CGP), a critical tool for advancing research in therapy selection and clinical trial eligibility.
The TSO 500 v2 research assay is now available with built-in HRD (homologous recombination deficiency) biomarker detection, offering more comprehensive insights for cancer researchers. It also features a faster turnaround time and requires lower tissue sample input, streamlining the sample-to-analysis workflow.
This launch reflects Illumina's commitment to providing high-quality and rigorously tested solutions to its customers. The improved efficiency and expanded capabilities of TSO 500 v2 are expected to broaden access to critical biomarker testing and support the development of precision medicine in oncology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.